Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CONZIP vs ACEPHEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tramadol hydrochloride (opioid agonist) and acetaminophen (centrally acting analgesic). Tramadol binds to mu-opioid receptors and inhibits serotonin and norepinephrine reuptake; acetaminophen inhibits cyclooxygenase (COX) and activates descending serotonergic pathways.
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Moderate to moderately severe pain,Pain management in adults
Mild to moderate pain,Fever
100 mg to 300 mg orally once daily with food. Initiate at 100 mg daily and titrate up by 100 mg increments every 4-7 days based on tolerability. Maximum dose 300 mg daily.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
Terminal elimination half-life: 3-4 hours for tramadol, 5-9 hours for M1 metabolite; clinically, dosing interval is 4-6 hours
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Tramadol: hepatic via CYP2D6 and CYP3A4 to active M1 metabolite; acetaminophen: hepatic via conjugation (glucuronidation, sulfation) and CYP2E1 (minor).
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
~60% renal (unchanged drug and glucuronide conjugates), ~35% fecal
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
~20% bound to plasma proteins (primarily albumin)
Approximately 10-20% bound to serum albumin; extensive tissue binding.
3.9 L/kg (tramadol), indicating extensive tissue distribution
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Oral: 75% (immediate-release); extended-release: ~100% relative to immediate-release
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
For creatinine clearance (Cr Cl) 60-89 m L/min: no adjustment. For Cr Cl 30-59 m L/min: reduce dose by 30% (e.g., start 70 mg daily). For Cr Cl 15-29 m L/min: reduce dose by 50% (e.g., start 50 mg daily). For Cr Cl <15 m L/min: not recommended. Hemodialysis: administer dose after dialysis on dialysis days; reduce dose by 70%.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
For Child-Pugh Class A (mild): no adjustment. For Child-Pugh Class B (moderate): reduce dose by 50% (e.g., start 50 mg daily). For Child-Pugh Class C (severe): not recommended (or maximum 50 mg daily with caution).
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
Safety and efficacy not established in pediatric patients (<18 years). No recommended dosage.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
For patients ≥65 years: initiate at 100 mg daily. Use caution and monitor for confusion and sedation. Consider reducing dose to 50 mg daily if tolerability issues arise.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion (especially in children); ultra-rapid metabolism of tramadol to O-desmethyltramadol (M1) in CYP2D6 poor metabolizers leading to toxicity; neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risks from concomitant use with benzodiazepines or other CNS depressants.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Respiratory depression; seizure risk (especially with CNS depressants, MAOIs, SSRIs, SNRIs); serotonin syndrome; increased intracranial pressure; severe hypotension; head injury; acute abdominal conditions; renal/hepatic impairment; elderly; debilitated patients; drug dependence; withdrawal; pregnancy; nursing mothers; CYP2D6 ultrarapid metabolizers; concomitant use with alcohol or other CNS depressants.
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Hypersensitivity to tramadol, acetaminophen, or any component; significant respiratory depression; acute or severe bronchial asthma; gastrointestinal obstruction (including paralytic ileus); use of MAOIs within 14 days; treatment of acute severe asthma exacerbation; concurrent use of linezolid; known history of prolonged QT interval or QT prolongation risk factors (tramadol component); severe hepatic impairment (acetaminophen).
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
Grapefruit and grapefruit juice may increase tramadol levels by inhibiting CYP3A4 metabolism. Avoid excessive caffeine as it may increase seizure risk. Food does not significantly affect absorption; may be taken with or without food.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
CONZIP (tramadol hydrochloride) is FDA Pregnancy Category C. In first trimester, cross-reactivity with opioid receptors raises concern for neural tube defects based on animal studies; human data limited but not excluded. In second and third trimesters, prolonged use may cause fetal opioid dependence and neonatal abstinence syndrome (NAS). Near term, use may lead to respiratory depression in the neonate.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Tramadol is excreted into breast milk. M/P ratio approximately 0.94 for tramadol and 0.8 for O-desmethyltramadol (active metabolite). Infant exposure estimated at 2.24% of maternal weight-adjusted dose. May cause drowsiness or poor feeding in infants; not recommended during breastfeeding unless benefit outweighs risk.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
No specific dose adjustment guidelines; pregnancy may increase clearance of tramadol, potentially reducing efficacy, but safety data insufficient to recommend dose increase. Use lowest effective dose for shortest duration. Chronic use may require slow taper to prevent withdrawal.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
CONZIP (tramadol hydrochloride) is a centrally acting opioid analgesic with additional serotonin and norepinephrine reuptake inhibition. It has a lower risk of respiratory depression compared to typical opioids but carries risks of seizures, especially in patients with epilepsy, head trauma, or those taking SSRIs, SNRIs, or MAOIs. CYP2D6 poor metabolizers may have reduced efficacy. Do not exceed 400 mg/day (300 mg in elderly >75 years). Avoid sudden discontinuation to prevent withdrawal syndrome.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol, sedatives, and other CNS depressants as they increase risk of severe drowsiness and respiratory depression.,Do not stop suddenly; taper dose under medical supervision to prevent withdrawal symptoms.,May cause dizziness or drowsiness; avoid driving or operating machinery until you know how you react.,Risk of serotonin syndrome when combined with other serotonergic drugs; report symptoms like agitation, high fever, or muscle twitching.,If you have a history of seizures, inform your doctor; tramadol may lower seizure threshold.,Swallow tablets whole; do not crush, chew, or split extended-release tablets.,Store in original container away from moisture and heat.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CONZIP vs ACEPHEN, answered by our medical review team.
CONZIP is a Opioid Analgesic that works by Tramadol hydrochloride (opioid agonist) and acetaminophen (centrally acting analgesic). Tramadol binds to mu-opioid receptors and inhibits serotonin and norepinephrine reuptake; acetaminophen inhibits cyclooxygenase (COX) and activates descending serotonergic pathways.. ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CONZIP and ACEPHEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CONZIP is: 100 mg to 300 mg orally once daily with food. Initiate at 100 mg daily and titrate up by 100 mg increments every 4-7 days based on tolerability. Maximum dose 300 mg daily.. The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CONZIP and ACEPHEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CONZIP is classified as Category C. CONZIP (tramadol hydrochloride) is FDA Pregnancy Category C. In first trimester, cross-reactivity with opioid receptors raises concern for neural tube defects based on animal studi. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.